hCG Priming in Women With Diminished Ovarian Reserve
Recruiting
Phase 3
Interventional Study
Infertility, Female
Ovarian Reserve
In Vitro Fertilization (IVF)
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 40
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- Kristine Loessl · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of this randomized controlled trial is to further examine the possible effects of low dose human chorionic gonadotropin (hCG) priming for eight weeks in women with diminished ovarian reserve (DOR) undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The investigators want to retest the findings of our first study in an identical paired design (NCT04643925), as a…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18-40 (both inclusive)
* Regular menstrual cycle (23-35 days)
* 1.-5. IVF/ICSI cycle at inclusion
* AMH \< 6.29 pmol/L (Elecsys® AMH assay)
Exclusion Criteria:
* Uterine malformations or hydrosalpinx
* Submucosal uterine myomas
* Uterine polyps
* Allergy to standard IVF/…
Contacts